Prevalence and factors related to hepatitis B and C infection in inflammatory bowel disease patients in China: A retrospective study

Journal of Crohn's and Colitis

Volumn 8, Issue 4, 2014, Pages 282-287

  Huang, Mei Lan ^a   Xu, Xi Tao ^a   Shen, Jun ^a   Qiao, Yu Qi ^a   Dai, Zhang Han ^a   Ran, Zhi Hua ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Crohn's disease; Hepatitis B; Hepatitis C; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB;

ADULT; AGE; ARTICLE; CHINA; CHINESE; CONTROLLED STUDY; CROHN DISEASE; FAMILY HISTORY; FEMALE; HEPATITIS B; HEPATITIS C; HOSPITAL ADMISSION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY BOWEL DISEASE; INTESTINE SURGERY; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIDDLE AGED; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; ULCERATIVE COLITIS; VACCINATION; CASE CONTROL STUDY; COMPLICATION; EPIDEMIOLOGY; VIROLOGY;

ADULT; CASE-CONTROL STUDIES; CHINA; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; HEPATITIS B; HEPATITIS B VACCINES; HEPATITIS C; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84895425073     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2013.08.017     Document Type: Article

References (32)

1. Biancone L., Pavia M., Del Vecchio Blanco G., D'Incà R., Castiglione F., De Nigris F., et al. Hepatitis B and C virus infection in Crohn's disease. Inflamm Bowel Dis 2001, 7(4):287-294.
2. Bargiggia S., Thorburn D., Anderloni A., Ardizzone S., Giorgi A., Bianchi Porro G., et al. Is interferon-alpha therapy safe and effective for patients with chronic hepatitis C and inflammatory bowel disease? A case-control study. Aliment Pharmacol Ther 2005, 22(3):209-215.
3. Longo F., Hebuterne X., Tran A., Staccini P., Hastier P., Schneider S., et al. Prevalence of hepatitis C in patients with chronic inflammatory bowel disease in the region of Nice and evaluation of risk factors. Gastroenterol Clin Biol 2000, 24(1):77-81.
4. Papa A., Felice C., Marzo M., Andrisani G., Armuzzi A., Covino M., et al. Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-alpha agents. J Crohns Colitis 2013, 7(2):113-119.
5. Gisbert J.P., Chaparro M., Esteve M. Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2011, 33(6):619-633.
6. Katsanos K.H., Tsianos V.E., Zois C.D., Zioga H., Vagias I., Zervou E., et al. Inflammatory bowel disease and hepatitis B and C in Western Balkans: a referral centre study and review of the literature. J Crohns Colitis 2010, 4(4):450-465.
7. Chevaux J.B., Nani A., Oussalah A., Venard V., Bensenane M., Belle A., et al. Prevalence of hepatitis B and C and risk factors for nonvaccination in inflammatory bowel disease patients in Northeast France. Inflamm Bowel Dis 2010, 16(6):916-924.
8. Toruner M., Loftus E.V., Harmsen W.S., Zinsmeister A.R., Orenstein R., Sandborn W.J., et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008, 134(4):929-936.
9. Garcia-Vidal C., Rodríguez-Fernández S., Teijón S., Esteve M., Rodríguez-Carballeira M., Lacasa J.M., et al. Risk factors for opportunistic infections in infliximab-treated patients: the importance of screening in prevention. Eur J Clin Microbiol Infect Dis 2009, 28(4):331-337.
10. Esteve M., Saro C., González-Huix F., Suarez F., Forné M., Viver J.M. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004, 53(9):1363-1365.
11. Ueno Y., Tanaka S., Shimamoto M., Miyanaka Y., Hiyama T., Ito M., et al. Infliximab therapy for Crohn's disease in a patient with chronic hepatitis B. Dig Dis Sci 2005, 50(1):163-166.
12. Parke F.A., Reveille J.D. Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. Arthritis Rheum 2004, 51(5):800-804.
13. Aslanidis S., Vassiliadis T., Pyrpasopoulou A., Douloumpakas I., Zamboulis C. Inhibition of TNFalpha does not induce viral reactivation in patients with chronic hepatitis C infection: two cases. Clin Rheumatol 2007, 26(2):261-264.
14. Lok A.S., McMahon B.J. Chronic hepatitis B. Hepatology 2007, 45(2):507-539.
15. Shouval D. Hepatitis B, vaccines. J Hepatol 2003, 39(Suppl. 1):S70-S76.
16. Loras C., Saro C., Gonzalez-Huix F., Mínguez M., Merino O., Gisbert J.P., et al. Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: a nationwide, multicenter study. Am J Gastroenterol 2009, 104(1):57-63.
17. Silverberg M.S., Satsangi J., Ahmad T., Arnott I.D., Bernstein C.N., Brant S.R., et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party o the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005, 19(Suppl. A):5-36.
18. Wang Y.B., Chen E.Q., Cui Y.L., Zeng L., Wang Y.J., Tang H. Seroprevalence of hepatitis B virus markers in individuals for physical examination in West China Hospital, China. Eur Rev Med Pharmacol Sci 2011, 15(6):592-596.
19. Liang X., Bi S., Yang W., Wang L., Cui G., Cui F., et al. Epidemiological serosurvey of hepatitis B in China-declining HBV prevalence due to hepatitis B vaccination. Vaccine 2009, 27(47):6550-6557.
20. Chen Y.S., Li L., Cui F.Q., Xing W.G., Wang L., Jia Z.Y., et al. A sero-epidemiological study on hepatitis C in China. Zhonghua Liu Xing Bing Xue Za Zhi 2011, 32(9):888-891.
21. Tolentino Y.F., Fogaca H.S., Zaltman C., Ximenes L.L., Coelho H.S. Hepatitis B virus prevalence and transmission risk factors in inflammatory bowel disease patients at Clementina Fraga Filho University Hospital. World J Gastroenterol 2008, 14(20):3201-3206.
22. Melmed G.Y., Ippoliti A.F., Papadakis K.A., Tran T.T., Birt J.L., Lee S.K., et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol 2006, 101(8):1834-1840.
23. Vento S., Cainelli F., Longhi M.S. Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue. Lancet Oncol 2002, 3(6):333-340.
24. Ostuni P., Botsios C., Punzi L., Sfriso P., Todesco S. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 2003, 62(2):686-687.
25. Michel M., Duvoux C., Hezode C., Cherqui D. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease. J Rheumatol 2003, 30(7):1624-1625.
26. del Valle García-Sánchez M., Gómez-Camacho F., Poyato-González A., Iglesias-Flores E.M., de Dios-Vega J.F., Sancho-Zapatero R. Infliximab therapy in a patient with Crohn's disease and chronic hepatitis B virus infection. Inflamm Bowel Dis 2004, 10(5):701-702.
27. Iannitto E., Minardi V., Calvaruso G., Mulè A., Ammatuna E., Di Trapani R., et al. Hepatitis B virus reactivation and alemtuzumab therapy. Eur J Haematol 2005, 74(3):254-258.
28. Law J.K., Ho J.K., Hoskins P.J., Erb S.R., Steinbrecher U.P., Yoshida E.M. Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. Leuk Lymphoma 2005, 46(7):1085-1089.
29. Madonia S., Orlando A., Scimeca D., Olivo M., Rossi F., Cottone M. Occult hepatitis B and infliximab-induced HBV reactivation. Inflamm Bowel Dis 2007, 13(4):508-509.
30. Loras C., Gisbert J.P., Mínguez M., Merino O., Bujanda L., Saro C., et al. Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. Gut 2010, 59(10):1340-1346.
31. Raimondo G., Navarra G., Mondello S., Costantino L., Colloredo G., Cucinotta E., et al. Occult hepatitis B virus in liver tissue of individuals without hepatic disease. J Hepatol 2008, 48(5):743-746.
32. Manzini P., Girotto M., Borsotti R., Giachino O., Guaschino R., Lanteri M., et al. Italian blood donors with anti-HBc and occult hepatitis B virus infection. Haematologica 2007, 92(12):1664-1670.